Good health!
Outdoor posters are getting bolder and bolder: Now they're even sneezing at us.
The Brazilian Ministry of Health wanted to encourage the population to get vaccinated against the flu. With vigor. Or rather: with water pressure. The CC&P agency from Brasília created a poster column that sprayed passers-by with water - and briefly made them believe that someone had sneezed on them. All you can really do is wish them "Good health!". (hae)
Good health!
Finanzen Ruf Lanz shows BB Biotech how research brings profit: for health - and on the stock market.
Finanzen Ruf Lanz shows BB Biotech how research brings profit: for health - and on the stock market.
Advertising for financial products is rarely a dream job for creatives. Most of the time, it involves depicting old men playing golf in the manner of crisp sports fans smiling off into the sunset somewhere with a feeling of absolute security. Ruf Lanz has now approached this task in a completely different way. BB Biotech is a company that invests in leading companies in the biotechnology sector and thus enables private and institutional investors to participate in their success. only around a third of the 35,000 or so known diseases are treatable. Only a fraction of these can be cured. Nevertheless, medical progress is unmistakable: thanks to biotechnologically produced drugs, therapies and medical interventions are now possible that were unthinkable ten years ago. Researchers in biotech laboratories are trying to understand the processes within the human body and its cells. One of the greatest successes of biotechnology is insulin, which was developed 30 years ago.
Today, thousands of biotech companies worldwide with hundreds of thousands of employees are researching new active ingredients and therapies for diseases such as cancer or Alzheimer's disease. More than every second newly approved drug now comes from the laboratories of the still young biotech industry. Demographics are increasing demand, as people in industrialized countries are getting older and older. Sales are growing rapidly and companies' development pipelines are full - for the dual benefit of patients and investors.
BB Biotech is one of the world's largest investors in the biotech sector and invests in successful companies in this long-term oriented industry worldwide. Since its initial listing in Switzerland in 1993, the BB Biotech share price has risen by 361 percent. The responsible asset manager is Bellevue Asset Management AG in Küsnacht, which together with Bank am Bellevue is part of Bellevue Group AG.
Performance: 361 percentNow, for the first time, BB Biotech has also invested in concise advertising. In order to draw the attention of new investors to BB Biotech, Ruf Lanz was commissioned to design a print campaign following a multi-stage presentation. The creative agency succeeded in getting to the heart of the complex topic in a striking and surprising way. Each of the three core messages was given its own subject: the "Lourdes" subject shows that, unfortunately, miracles cannot cure all diseases. Mankind remains dependent on innovative medicines. It is therefore worth investing in the medicines of tomorrow. The subject "Champagne from test tubes" visualizes the attractive performance since the initial listing in 1993. And the subject "Birthday cake with 120 candles" dramatizes the constantly increasing demand for biotech products because people are getting older and older.
The advertisements have been appearing in business publications in Switzerland and Germany since mid-November.
Andreas Panzeri
Advertising for financial products is rarely a dream job for creatives. Most of the time, it involves depicting old men playing golf in the manner of crisp sports fans smiling off into the sunset somewhere with a feeling of absolute security. Ruf Lanz has now approached this task in a completely different way. BB Biotech is a company that invests in leading companies in the biotechnology sector and thus enables private and institutional investors to participate in their success. only around a third of the 35,000 or so known diseases are treatable. Only a fraction of these can be cured. Nevertheless, medical progress is unmistakable: thanks to biotechnologically produced drugs, therapies and medical interventions are now possible that were unthinkable ten years ago. Researchers in biotech laboratories are trying to understand the processes within the human body and its cells. One of the greatest successes of biotechnology is insulin, which was developed 30 years ago.
Today, thousands of biotech companies worldwide with hundreds of thousands of employees are researching new active ingredients and therapies for diseases such as cancer or Alzheimer's disease. More than every second newly approved drug now comes from the laboratories of the still young biotech industry. Demographics are increasing demand, as people in industrialized countries are getting older and older. Sales are growing rapidly and companies' development pipelines are full - for the dual benefit of patients and investors.
BB Biotech is one of the world's largest investors in the biotech sector and invests in successful companies in this long-term oriented industry worldwide. Since its initial listing in Switzerland in 1993, the BB Biotech share price has risen by 361 percent. The responsible asset manager is Bellevue Asset Management AG in Küsnacht, which together with Bank am Bellevue is part of Bellevue Group AG.
Performance: 361 percentNow, for the first time, BB Biotech has also invested in concise advertising. In order to draw the attention of new investors to BB Biotech, Ruf Lanz was commissioned to design a print campaign following a multi-stage presentation. The creative agency succeeded in getting to the heart of the complex topic in a striking and surprising way. Each of the three core messages was given its own subject: the "Lourdes" subject shows that, unfortunately, miracles cannot cure all diseases. Mankind remains dependent on innovative medicines. It is therefore worth investing in the medicines of tomorrow. The subject "Champagne from test tubes" visualizes the attractive performance since the initial listing in 1993. And the subject "Birthday cake with 120 candles" dramatizes the constantly increasing demand for biotech products because people are getting older and older.
The advertisements have been appearing in business publications in Switzerland and Germany since mid-November.
Andreas Panzeri
